Case Report
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Mar 16, 2016; 4(3): 88-93
Published online Mar 16, 2016. doi: 10.12998/wjcc.v4.i3.88
Combination therapy with daclatasvir and asunaprevir for dialysis patients infected with hepatitis C virus
Ken Sato, Yuichi Yamazaki, Tatsuya Ohyama, Takeshi Kobayashi, Norio Horiguchi, Satoru Kakizaki, Motoyasu Kusano, Masanobu Yamada
Ken Sato, Yuichi Yamazaki, Tatsuya Ohyama, Takeshi Kobayashi, Norio Horiguchi, Satoru Kakizaki, Masanobu Yamada, Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Gunma 371-8511, Japan
Ken Sato, Yuichi Yamazaki, Norio Horiguchi, Satoru Kakizaki, Department of Gastroenterology, Heisei Hidaka Clinic, Gunma 371-0001, Japan
Motoyasu Kusano, Department of Endoscopy and Endoscopic Surgery, Gunma University Hospital, Gunma 371-8511, Japan
Author contributions: Sato K drafted the article and analyzed and interpreted the data; Yamazaki Y, Ohyama T, Kobayashi T, Horiguchi N, Kakizaki S and Kusano M analyzed the data; Yamada M approved the final version to be published.
Institutional review board statement: The institutional review board in our institute does not require more than obtaining written informed consent for the publication of case reports.
Informed consent statement: We obtained written informed consent.
Conflict-of-interest statement: The authors have declared no conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Ken Sato, MD, PhD, Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan. satoken@gunma-u.ac.jp
Telephone: +81-272-208127 Fax: +81-272-208136
Received: November 6, 2015
Peer-review started: November 9, 2015
First decision: December 18, 2015
Revised: January 12, 2016
Accepted: January 29, 2016
Article in press: January 31, 2016
Published online: March 16, 2016
Processing time: 125 Days and 12.7 Hours
Core Tip

Core tip: Oral combination therapy with the direct-acting antiviral agents daclatasvir and asunaprevir, which are both metabolized largely in the liver, is a very useful strategy for dialysis patients infected with genotype 1b hepatitis C virus. Although there were only 4 dialysis patients, the combination therapy was effective and showed a relatively favorable safety profile. One patient was admitted for heart failure with or without pneumonitis and percutaneous coronary intervention, although the causal relationship between these adverse events and the combination therapy was interpreted as negative. Our case reports warrant further studies, although careful observation during the treatment is needed.